All‐oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub‐analysis in Asian patients from the HALLMARK DUAL study

Publisher： John Wiley & Sons Inc

E-ISSN： 1478-3231|36|10|1433-1441

ISSN： 1478-3223

Source： LIVER INTERNATIONAL (ELECTRONIC), Vol.36, Iss.10, 2016-10, pp. : 1433-1441

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study

By  

HEPATOLOGY, Vol. 61, Iss. 4, 2015-04 ,pp. : 1127-1135

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 6, 2015-03 ,pp. : 544-563

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma

By  

Oncology, Vol. 89, Iss. 2, 2015-0 ,pp. : 42-46

Karger

Access to resources Recommend Favorite

Emergence of resistant variants detected by ultra‐deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 2, 2015-02 ,pp. : 158-165

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease

By  

Oncology, Vol. 93, Iss. 2, 2017-04 ,pp. : 92-98

Karger

Access to resources Recommend Favorite